ACTR 001

Drug Profile

ACTR 001

Alternative Names: ACTR-001; Viral ACTR T-cells + rituximab

Latest Information Update: 19 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unum Therapeutics
  • Class Antineoplastics; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 19 Aug 2016 Discontinued - Preclinical for Non-Hodgkin's lymphoma in USA (Parenteral)
  • 14 Dec 2015 Preclinical trials in Non-Hodgkin's lymphoma in USA (Parenteral)
  • 14 Dec 2015 Unum Therapeutics plans a phase I trial for Non-Hodgkin lymphoma (Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top